Reduced oxidative stress in STEMI patients treated by primary percutaneous coronary intervention and with antioxidant therapy: A systematic review

Cardiovascular Drugs and Therapy

Volumn 28, Issue 2, 2014, Pages 173-181

  Ekeløf, Sarah ^a,c   Jensen, Svend Eggert ^b   Rosenberg, Jacob ^a   Gögenur, Ismail ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c NONE   (Denmark)

Author keywords

Acute myocardial infarction; Antioxidant therapy; Ischemia reperfusion injury; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLCYSTEINE; ALLOPURINOL; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; CATALASE; DEFEROXAMINE; GLUCOSE; GLUCOSE PLUS INSULIN PLUS POTASSIUM; GLUTATHIONE PEROXIDASE; INSULIN; ISOPROSTANE DERIVATIVE; MALONALDEHYDE; NICORANDIL; NORPHENAZONE; OXIDIZED LOW DENSITY LIPOPROTEIN; POTASSIUM; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOREDOXIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; CONTINUOUS INFUSION; DRUG EFFECT; EMBASE; HEART FUNCTION; HEART INDEX; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HUMAN; LOADING DRUG DOSE; MEDLINE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIOXIDANTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIUM; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84897061048     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6511-3     Document Type: Review

References (49)

1. Hausenloy DJ, Yellon DM. Time to take myocardial reperfusion injury seriously. N Engl J Med. 2008;359:518-20.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-35.
3. Qin C, Yap S, Woodman OL. Antioxidants in the prevention of myocardial ischemia/reperfusion injury. Expert Rev Clin Pharmacol. 2009;2:673-95.
4. Stebbins A, Mehta RH, Armstrong PW, et al. A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv. 2010;3:414-22.
5. Tullio F, Angotti C, Perrelli M-G, Penna C, Pagliaro P. Redox balance and cardioprotection. Basic Res Cardiol. 2012;108:392.
6. Perrelli MG, Pagliaro P, Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species. World J Cardiol. 2011;3:186-200.
7. Berg K, Jynge P, Bjerve K, Skarra S, Basu S, Wiseth R. Oxidative stress and inflammatory response during and following coronary interventions for acute myocardial infarction. Free Radic Res. 2005;39:629-36.
8. Kijima Y, Hashimura K, Matsu-ura Y, et al. Transcardiac 8-iso-prostaglandin F(2 alpha) generation from acute myocardial infarction heart: insight into abrupt reperfusion and oxidant stress. Prostaglandins Leukot Essent Fat Acids. 2001;64:161-6.
9. Sugamura K, Keaney Jr JF. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. 2011;51:978-92.
10. Kutala VK, Khan M, Angelos MG, Kuppusamy P. Role of oxygen in postischemic myocardial injury. Antioxid Redox Signal. 2007;9:1193-206.
11. Himmetoglu S, Dincer Y, Bozcali E, Ali Vural V, Akcay T. Oxidative DNA damage and antioxidant defense after reperfusion in acute myocardial infarction. J Investig Med. 2009;57:595-9.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-94.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
14. Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J. 2006;70:832-7.
15. Guan W, Osanai T, Kamada T, et al. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol. 2003;41:699-705.
16. Guan W, Osanai T, Kamada T, Ishizaka H, Hanada H, Okumura K. Time course of free radical production after primary coronary angioplasty for acute myocardial infarction and the effect of vitamin C. Jpn Circ J. 1999;63:924-8.
17. Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004;148:E15.
18. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Protective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010;55:2201-9.
19. Díaz-Araya G, Nettle D, Castro P, et al. Oxidative stress after reperfusion with primary coronary angioplasty: lack of effect of glucose-insulin-potassium infusion. Crit Care Med. 2002;30:417-21.
20. Chan W, Taylor AJ, Ellims AH, et al. Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction. Circ Cardiovasc Interv. 2012;5:270-8.
21. Chen M, Li H, Wang Y. Protection by atorvastatin pretreatment in patients undergoing primary percutaneous coronary intervention is associated with the lower levels of oxygen free radicals. J Cardiovasc Pharmacol. 2013;62:320-4.
22. Carreira RS, Monteiro P, Kowaltowski AJ, Goncalves LM, Providência LA. Nicorandil protects cardiac mitochondria against permeability transition induced by ischemia-reperfusion. J Bioenerg Biomembr. 2008;40:95-102.
23. Pieper GM, Gross GJ. Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil. Cardiovasc Drugs Ther. 1992;6:225-32.
24. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-82.
25. Demircan S, Yazici M, Diraman E, et al. The effect of glucose-insulin-potassium treatment on myocardial oxidative stress in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Coron Artery Dis. 2008;19:99-104.
26. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004;173:1-12.
27. Wassmann S, Laufs U, Müller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-5.
28. Reilly MP, Delanty N, Roy L, et al. Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. 1997;96:3314-20.
29. Molyneux CA, Glyn MC, Ward BJ. Oxidative stress and cardiac microvascular structure in ischemia and reperfusion: the protective effect of antioxidant vitamins. Microvasc Res. 2002;64:265-77.
30. Kinugasa Y, Ogino K, Furuse Y, et al. Allopurinol improves cardiac dysfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts. Circ J. 2003;67:781-7.
31. Williams RE, Zweier JL, Flaherty JT. Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation. 1991;83:1006-14.
32. Han B, Zhang X, Zhang Q, et al. Protective effects of salvianolate on microvascular flow in a porcine model of myocardial ischaemia and reperfusion. Arch Cardiovasc Dis. 2011;104:313-24.
33. Onogi H, Minatoguchi S, Chen X-H, et al. Edaravone reduces myocardial infarct size and improves cardiac function and remodelling in rabbits. Clin Exp Pharmacol Physiol. 2006;33:1035-41.
34. Tsujita K, Shimomura H, Kawano H, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004;94:481-4.
35. Nakamura Y, Yamada Y, Shimomura H, et al. Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. J Cardiol. 2009;54:416-24.
36. Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010;145:257-8.
37. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-8.
38. Sugimoto K, Ito H, Iwakura K, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J. 2003;67:295-300.
39. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33:654-60.
40. Kikuchi K, Takeshige N, Miura N, et al. Beyond free radical scavenging: beneficial effects of edaravone (Radicut) in various diseases (review). Exp Ther Med. 2012;3:3-8.
41. Wang A, Chen F, Xie Y, Guo Z, Yu Y. Protective mechanism of nicorandil on rat myocardial ischemia-reperfusion. J Cardiovasc Med (Hagerstown). 2012;13:511-5.
42. Qian J, Keyes KT, Long B, Chen G, Ye Y. Impact of HMG-CoA reductase inhibition on oxidant-induced injury in human retinal pigment epithelium cells. J Cell Biochem. 2011;112:2480-9.
43. Pisarenko OI, Lakomkin VL, Studneva IM, et al. Allopurinol-enhanced postischemic recovery in the isolated rat heart involves repletion of high-energy phosphates. Biochem Med Metab Biol. 1994;51:16-26.
44. Chambers DJ, Takahashi A, Humphrey SM, Harvey DM, Hearse DJ. Allopurinol-enhanced myocardial protection does not involve xanthine oxidase inhibition or purine salvage. Basic Res Cardiol. 1992;87:227-38.
45. Pain T, Yang XM, Critz SD, Yue Y, Nakano A, Liu GS, et al. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals. Circ Res. 2000;87:460-6.
46. Penna C, Mancardi D, Rastaldo R, Pagliaro P. Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim Biophys Acta. 2009;1787:781-93.
47. Penna C, Rastaldo R, Mancardi D, et al. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol. 2006;101:180-9.
48. Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol. 2008;103:464-71.
49. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009;104:189-202.